PA8570001A1 - Aminoacidos con afinidad por la proteina a2 delta - Google Patents

Aminoacidos con afinidad por la proteina a2 delta

Info

Publication number
PA8570001A1
PA8570001A1 PA20038570001A PA8570001A PA8570001A1 PA 8570001 A1 PA8570001 A1 PA 8570001A1 PA 20038570001 A PA20038570001 A PA 20038570001A PA 8570001 A PA8570001 A PA 8570001A PA 8570001 A1 PA8570001 A1 PA 8570001A1
Authority
PA
Panama
Prior art keywords
delta
amino acids
affinity
protein
subunity
Prior art date
Application number
PA20038570001A
Other languages
English (en)
Spanish (es)
Inventor
David Juergen Wustrow
Nancy Sue Barta
Jacob Bradley Schwartz
Andrew John Thorpe
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=28675482&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PA8570001(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of PA8570001A1 publication Critical patent/PA8570001A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/08—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to hydrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/28—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
PA20038570001A 2002-03-28 2003-03-28 Aminoacidos con afinidad por la proteina a2 delta PA8570001A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36841302P 2002-03-28 2002-03-28

Publications (1)

Publication Number Publication Date
PA8570001A1 true PA8570001A1 (es) 2003-12-10

Family

ID=28675482

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20038570001A PA8570001A1 (es) 2002-03-28 2003-03-28 Aminoacidos con afinidad por la proteina a2 delta

Country Status (42)

Country Link
US (3) US7064147B2 (https=)
EP (2) EP1492761B1 (https=)
JP (2) JP3831379B2 (https=)
KR (2) KR100694719B1 (https=)
CN (2) CN1817854A (https=)
AP (1) AP1791A (https=)
AR (2) AR039154A1 (https=)
AU (1) AU2003208538B2 (https=)
BR (1) BR0308814A (https=)
CA (1) CA2480872C (https=)
CR (1) CR7501A (https=)
CU (1) CU23331B7 (https=)
CY (1) CY1109304T1 (https=)
DE (1) DE60328469D1 (https=)
DK (1) DK1492761T3 (https=)
EA (2) EA200501497A1 (https=)
EC (1) ECSP045319A (https=)
ES (1) ES2327910T3 (https=)
GE (2) GEP20084298B (https=)
GT (2) GT200300072AA (https=)
HR (2) HRP20040891A2 (https=)
IL (2) IL164110A0 (https=)
IS (2) IS7451A (https=)
MA (1) MA27188A1 (https=)
MX (1) MXPA04009373A (https=)
MY (1) MY131424A (https=)
NI (1) NI200300043A (https=)
NO (2) NO20044614L (https=)
NZ (2) NZ541320A (https=)
OA (1) OA12795A (https=)
PA (1) PA8570001A1 (https=)
PE (1) PE20040349A1 (https=)
PL (1) PL209750B1 (https=)
PT (1) PT1492761E (https=)
RS (2) RS83604A (https=)
SI (1) SI1492761T1 (https=)
TN (1) TNSN04186A1 (https=)
TW (1) TWI225864B (https=)
UA (2) UA80116C2 (https=)
UY (1) UY27738A1 (https=)
WO (1) WO2003082807A2 (https=)
ZA (1) ZA200407536B (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10129693A1 (de) * 2001-06-22 2003-01-02 Jan Loock Verfahren zur extrakorporalen qualitativen und/oder quantitativen Erfassung neurotoxischer Substanzen im Blutplasma eines Individuums
NI200300043A (es) * 2002-03-28 2003-11-05 Warner Lambert Co AMINOACIDOS CON AFINIDAD POR LA PROTEINA a2DELTA.
US7419981B2 (en) 2002-08-15 2008-09-02 Pfizer Inc. Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor
CA2451267A1 (en) 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
WO2005002585A1 (en) * 2003-07-02 2005-01-13 Warner-Lambert Company Llc Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor
BRPI0414798A (pt) 2003-09-25 2006-11-21 Warner Lambert Co métodos para usar aminoácidos com afinidade para a proteìna alfa2delta
BRPI0414781A (pt) 2003-09-25 2006-11-21 Warner Lambert Co aminoácidos com afinidade para a proteìna (alfa)2(delta)
RU2335342C2 (ru) * 2004-03-12 2008-10-10 Уорнер-Ламберт Компани Ллс C1-симметричные бисфосфиновые лиганды и их применение в асимметрическом синтезе прегабалина
US20090247743A1 (en) * 2004-07-09 2009-10-01 Pfizer Inc Preparation of beta-amino acids having affinity for the alpha-2-delta protein
WO2006092692A1 (en) * 2005-03-01 2006-09-08 Pfizer Limited Use of combinations of pde7 inhibitors and alpha-2-delty ligands for the treatment of neuropathic pain
KR20070107147A (ko) * 2005-03-24 2007-11-06 파마시아 앤드 업존 캄파니 엘엘씨 알파-2-델타 단백질에 친화성을 갖는 광학적으로 순수한베타-아미노산의 제조
WO2007052134A1 (en) * 2005-11-04 2007-05-10 Pfizer Limited (2s)-2-aminomethyl-5-ethyl heptanoic acid its pharmaceutical use
US20090286875A1 (en) * 2005-11-17 2009-11-19 Pfizer, Inc. Isocystene derivatives for the treatment of pain
CN101420947A (zh) * 2006-03-06 2009-04-29 辉瑞产品公司 用于非恢复性睡眠的α-2-δ配体
AR061728A1 (es) * 2006-06-30 2008-09-17 Pfizer Prod Inc Composicion para tratamiento usando compuestos selectivos alfa-2-delta-1
US20110124705A1 (en) * 2009-11-24 2011-05-26 Xenoport, Inc. Prodrugs of alpha-2-delta ligands, pharmaceutical compositions and uses thereof
CA2836449C (en) 2011-05-17 2021-04-27 The Regents Of The University Of California Kinase inhibitors
EA025496B1 (ru) 2011-05-17 2016-12-30 Принсипиа Биофарма Инк. Ингибиторы тирозинкиназы
US9376438B2 (en) 2011-05-17 2016-06-28 Principia Biopharma, Inc. Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
CN103164756A (zh) * 2011-12-12 2013-06-19 苏州艾隆科技有限公司 贵重药品的管理方法及其系统
ME03455B (me) 2012-09-10 2020-01-20 Principia Biopharma Inc Jedinjenja pirazolopirimidina kao inhibitori kinaze
US8957080B2 (en) 2013-04-09 2015-02-17 Principia Biopharma Inc. Tyrosine kinase inhibitors
PT3107544T (pt) 2014-02-21 2021-01-05 Principia Biopharma Inc Sais e forma sólida de um inibidor de btk
US10485797B2 (en) 2014-12-18 2019-11-26 Principia Biopharma Inc. Treatment of pemphigus
TW201718572A (zh) 2015-06-24 2017-06-01 普林斯匹亞生物製藥公司 酪胺酸激酶抑制劑
MA45547A (fr) 2016-06-29 2019-05-08 Principia Biopharma Inc Formulations à libération modifiée à base de 2-[3-[4-amino-3-(2-fluoro-4-phénoxy-phényl)pyrazolo[3,4-d]pyrimidine-1-yl]pipéridine-1-carbonyl]-4-méthyl-4-[4-(oxétane-3-yl)pipérazine-1-yl]pent-2-ènenitrile
TWI877239B (zh) 2019-10-14 2025-03-21 美商普林斯匹亞生物製藥公司 藉由投予(R)-2-[3-[4-胺基-3-(2-氟-4-苯氧基-苯基)吡唑并[3,4-d]嘧啶-1-基]哌啶-1-羰基]-4-甲基-4-[4-(氧呾-3-基)哌-1-基]戊-2-烯腈來治療免疫血小板減少症之方法
JP2023511105A (ja) 2020-01-22 2023-03-16 プリンシピア バイオファーマ インコーポレイテッド ２－［３－［４－アミノ－３－（２－フルオロ－４－フェノキシ－フェニル）－１ｈ－ピラゾロ［３，４－ｄ］ピリミジン－１－イル］ピペリジン－１－カルボニル］－４－メチル－４－［４－（オキセタン－３－イル）ピペラジン－１－イル］ペンタ－２－エンニトリルの結晶形態
WO2025078915A1 (en) * 2023-10-12 2025-04-17 Siemens Healthcare Diagnostics Inc. Pregabalin haptens, immunogens, and protein conjugates and methods of production and use thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1377736A (fr) * 1962-12-21 1964-11-06 Hoffmann La Roche Procédé pour la préparation d'acides amino-carboxyliques
FR1377366A (fr) 1963-08-19 1964-11-06 Dispositif de protection de sécurité pour appareils électriques
KR880007441A (ko) * 1986-12-11 1988-08-27 알렌 제이.스피겔 스피로-치환된 글루타르아미드 이뇨제
AU7168091A (en) 1989-12-22 1991-07-24 Schering Corporation Mercaptocycloacyl aminoacid endopeptidase inhibitors
US5614498A (en) 1990-06-07 1997-03-25 Banyu Pharmaceutical Co., Ltd. Endothelin antagonistic substance
US5011066A (en) * 1990-07-27 1991-04-30 Motorola, Inc. Enhanced collapse solder interconnection
US5239113A (en) 1991-10-15 1993-08-24 Monsanto Company Substituted β-amino acid derivatives useful as platelet aggregation inhibitors and intermediates thereof
EP0561758A3 (en) 1992-03-18 1995-04-05 Monsanto Co Method of preparing optically active homo-beta-amino acids
US5578606A (en) * 1992-10-30 1996-11-26 G. D. Searle & Co. α- and β-amino acid hydroxyethylamino sulfonyl urea derivatives useful as retroviral protease inhibitors
CA2176140A1 (en) 1993-11-24 1995-06-01 Meng Hsin Chen Indolyl group containing compounds and the use thereof to promote the release of growth hormone(s)
JPH09506369A (ja) 1993-12-12 1997-06-24 アグロジーン・リミテッド 菌類感染から植物を保護するための新規方法
US5472830A (en) 1994-04-18 1995-12-05 Ocg Microelectronic Materials, Inc. Non-corrosion photoresist stripping composition
JP2000514809A (ja) 1996-07-12 2000-11-07 ジー．ディー．サール アンド カンパニー キラルβ―アミノ酸の不斉合成
ATE361909T1 (de) * 1996-10-23 2007-06-15 Warner Lambert Co Substituierte gamma-aminobuttersäurederivate als arzneimittel
US6306909B1 (en) * 1997-03-12 2001-10-23 Queen's University At Kingston Anti-epileptogenic agents
GB2323594A (en) 1997-03-25 1998-09-30 Victor Martin 2-amino-alkanoic acid derivatives, 2-amino alcohols and diamines
US6201023B1 (en) 1997-06-10 2001-03-13 Agrogene Ltd. Methods and compositions to protect crops against plant parasitic nematodes
US6011066A (en) 1998-02-02 2000-01-04 Veterans General Hospital-Taipei Method for treating septic shock
CN1297354A (zh) 1998-03-16 2001-05-30 西托维亚公司 二肽卡斯帕酶抑制剂及其用途
EP1013769A1 (en) 1998-12-22 2000-06-28 Dsm N.V. Process for the enzymatic preparation of amino acid derivatives with enhanced optical purity
FR2791982B1 (fr) 1999-04-06 2002-12-27 Inst Nat Sante Rech Med Inhibiteurs de lta4 hydrolase et leurs applications therapeutiques.
ES2317839T3 (es) * 1999-06-10 2009-05-01 Warner-Lambert Company Llc Acidos 3-propil gamma-aminobutiricos monosustituidos.
JP2003533223A (ja) * 2000-05-16 2003-11-11 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー α２δ２カルシウムチャネルサブユニットの発現細胞株
EP1282594A1 (en) 2000-05-17 2003-02-12 Medivir UK Ltd Branched amino acids
MXPA03002090A (es) 2000-09-14 2003-06-19 Gruenenthal Gmbh °-tio-aminoacidos.
DE10048715A1 (de) 2000-09-30 2004-05-19 Grünenthal GmbH Verwendung von Aminosäure zur Behandlung von Schmerz
CA2440834A1 (en) * 2001-03-13 2002-09-19 Queen's University At Kingston Anti-epileptogenic agents
NI200300043A (es) * 2002-03-28 2003-11-05 Warner Lambert Co AMINOACIDOS CON AFINIDAD POR LA PROTEINA a2DELTA.
GB0219024D0 (en) * 2002-08-15 2002-09-25 Pfizer Ltd Synergistic combinations
CN1228312C (zh) * 2002-12-27 2005-11-23 中国科学院化学研究所 以酮为原料合成β—氨基酸的方法

Also Published As

Publication number Publication date
RS83604A (sr) 2007-02-05
GT200300072A (es) 2004-01-21
EP1492761B1 (en) 2009-07-22
IS7451A (is) 2004-09-16
UA80018C2 (en) 2007-08-10
ES2327910T3 (es) 2009-11-05
HK1076627A1 (zh) 2006-01-20
US20050272783A1 (en) 2005-12-08
NO20044614L (no) 2004-12-01
EP1614675A3 (en) 2006-03-29
TWI225864B (en) 2005-01-01
UA80116C2 (en) 2007-08-27
UY27738A1 (es) 2003-10-31
SI1492761T1 (sl) 2009-12-31
EA200501497A1 (ru) 2006-06-30
AR039154A1 (es) 2005-02-09
IL169820A0 (en) 2007-07-04
JP2006028189A (ja) 2006-02-02
JP3857714B2 (ja) 2006-12-13
US7064147B2 (en) 2006-06-20
WO2003082807A3 (en) 2003-12-24
US20060154972A1 (en) 2006-07-13
EA008709B1 (ru) 2007-06-29
TNSN04186A1 (fr) 2007-03-12
PT1492761E (pt) 2009-09-03
GEP20074123B (en) 2007-06-11
KR20040094882A (ko) 2004-11-10
EP1614675A2 (en) 2006-01-11
CN100462351C (zh) 2009-02-18
CR7501A (es) 2005-01-24
US7517909B2 (en) 2009-04-14
CN1817854A (zh) 2006-08-16
PE20040349A1 (es) 2004-06-19
JP3831379B2 (ja) 2006-10-11
OA12795A (en) 2006-07-18
NZ535364A (en) 2007-05-31
NI200300043A (es) 2003-11-05
BR0308814A (pt) 2005-01-04
IL164110A0 (en) 2005-12-18
KR100630981B1 (ko) 2006-10-04
CN1653036A (zh) 2005-08-10
KR100694719B1 (ko) 2007-03-16
HRP20050764A2 (en) 2006-02-28
CA2480872A1 (en) 2003-10-09
IS7951A (is) 2005-07-21
CU23331B7 (es) 2008-12-24
NO20053918L (no) 2004-12-01
TW200305576A (en) 2003-11-01
ECSP045319A (es) 2004-11-26
AP1791A (en) 2007-10-15
CY1109304T1 (el) 2014-07-02
AP2004003144A0 (en) 2004-09-30
MA27188A1 (fr) 2005-01-03
US20030195251A1 (en) 2003-10-16
CA2480872C (en) 2011-02-15
MXPA04009373A (es) 2005-01-25
WO2003082807A2 (en) 2003-10-09
HRP20040891A2 (en) 2004-12-31
NZ541320A (en) 2007-01-26
MY131424A (en) 2007-08-30
GT200300072AA (es) 2006-08-23
GEP20084298B (en) 2008-01-25
EA200401127A1 (ru) 2005-06-30
AU2003208538B2 (en) 2009-07-16
AU2003208538A1 (en) 2003-10-13
PL373363A1 (en) 2005-08-22
KR20060007446A (ko) 2006-01-24
RS20050667A (sr) 2007-02-05
DE60328469D1 (de) 2009-09-03
JP2005521723A (ja) 2005-07-21
ZA200407536B (en) 2006-01-25
AR050261A2 (es) 2006-10-11
DK1492761T3 (da) 2009-09-28
EP1492761A2 (en) 2005-01-05
PL209750B1 (pl) 2011-10-31

Similar Documents

Publication Publication Date Title
PA8570001A1 (es) Aminoacidos con afinidad por la proteina a2 delta
CY1116992T1 (el) Μεθοδος θεραπειας της σκληρυνσης κατα πλακας αναστελλοντας τη δραση της il-17
EP1487493A4 (en) CONJUGATES OF THERAPEUTIC OR CYTOTOXIC AGENTS AND BIOACTIVE PEPTIDES
CY1105082T1 (el) Χρηση της φλιβανσepινης στην αγωγη διαταραχων της σεξουαλικης επιθυμιας
DK1178958T3 (da) N-cyanomethylamider som proteaseinhibitorer
CY1109972T1 (el) Χρηση τοξινης αλλαντιασης για τη θεραπευτικη αγωγη του πονου της νεραλγιας
CR8290A (es) AMINOACIDOS CON AFINIDAD POR LA PROTEINA a2-d
ECSP024352A (es) Nueva composicion farmaceutica
CY1106239T1 (el) ΦΑΡΜΑΚΕΥΤΙΚΕΣ ΔΙΑΜΟΡΦΩΣΕΙΣ ΕΛΕΓΧΟΜΕΝΗΣ ΑΠΕΛΕΥΘΕΡΩΣΗΣ ΠΟΥ ΠEPΙΕΧΟΥΝ ΑΝΑΣΤΟΛΕΑ cGMP PDE-5
CY1113789T1 (el) Συνδυασμοι απο ενεργοποιητες διαυλων καλιου και αναστολεις διαυλων νατριου ή δραστικες ουσιες που επηρεαζουν τους διαυλους νατριου για τη θεραπεια επωδυνων καταστασεων
ECSP066575A (es) Antagonistas del receptor b1 de bradiquinina
AR109644A2 (es) Pradofloxacina y composición farmacéutica para el tratamiento sistémico de enfermedades bacterianas en la cavidad bucal
PA8581801A1 (es) Formulaciones que contienen un compuesto de indolinona
CY1108599T1 (el) Η απλιδινη στην αντιμετωπιση του πολλαπλου μυελωματος
DE60102590T2 (de) Darreichungsformen zur behandlung von oralen mykosen
BRPI0414798A (pt) métodos para usar aminoácidos com afinidade para a proteìna alfa2delta
ATE383874T1 (de) Perylenequinonen zur anwendung als sonosensitizer
DOP2003000616A (es) Aminoacidos con afinidad por la proteina a2
ES2117475T5 (es) Utilizacion de acidos monocarboxilicos para el tratamiento de las materias queratinicas.
UY29033A1 (es) Aminoácidos con afinidad por la proteína a2o (alfa 2 delta)
DOP2004001000A (es) Aminoacidos con afinidad por la proteina
ITRM20010225A1 (it) Zoccoli autostimolanti per effettuare una terapia zonale con punti distimolazione variabili.
HN2003000108A (es) AMINOACIDOS CON AFINIDAD POR LA PROTEINA a2o´
GT200400189A (es) Aminoacidos con afinidad por la proteina a2d.
ATE404581T1 (de) Faserformgebende peptide, die mit selbstanordnenden peptiden interagieren